Credit Agricole S A Increases Holding in Amdocs LTD (DOX); Abbott Labs (ABT) Market Valuation Rose While Reilly Financial Advisors Has Lowered Stake

May 23, 2018 - By Hazel Jackson

Amdocs Limited (NASDAQ:DOX) Logo

Credit Agricole S A increased its stake in Amdocs Ltd (DOX) by 49.53% based on its latest 2017Q4 regulatory filing with the SEC. Credit Agricole S A bought 25,664 shares as the company’s stock rose 0.29% while stock markets declined. The institutional investor held 77,475 shares of the edp services company at the end of 2017Q4, valued at $5.07M, up from 51,811 at the end of the previous reported quarter. Credit Agricole S A who had been investing in Amdocs Ltd for a number of months, seems to be bullish on the $9.43 billion market cap company. The stock increased 0.06% or $0.04 during the last trading session, reaching $65.72. About 80,661 shares traded. Amdocs Limited (NASDAQ:DOX) has risen 6.08% since May 23, 2017 and is uptrending. It has underperformed by 5.47% the S&P500.

Reilly Financial Advisors Llc decreased its stake in Abbott Labs (ABT) by 11.26% based on its latest 2017Q4 regulatory filing with the SEC. Reilly Financial Advisors Llc sold 24,533 shares as the company’s stock rose 5.88% while stock markets declined. The institutional investor held 193,278 shares of the major pharmaceuticals company at the end of 2017Q4, valued at $11.03 million, down from 217,811 at the end of the previous reported quarter. Reilly Financial Advisors Llc who had been investing in Abbott Labs for a number of months, seems to be less bullish one the $108.37B market cap company. The stock increased 0.68% or $0.42 during the last trading session, reaching $61.81. About 895,324 shares traded. Abbott Laboratories (NYSE:ABT) has risen 34.85% since May 23, 2017 and is uptrending. It has outperformed by 23.30% the S&P500.

Among 25 analysts covering Abbott Laboratories (NYSE:ABT), 18 have Buy rating, 0 Sell and 7 Hold. Therefore 72% are positive. Abbott Laboratories had 107 analyst reports since July 24, 2015 according to SRatingsIntel. Jefferies maintained the stock with “Buy” rating in Wednesday, January 24 report. The stock of Abbott Laboratories (NYSE:ABT) earned “Buy” rating by Jefferies on Thursday, August 4. The firm has “Outperform” rating by RBC Capital Markets given on Friday, October 9. On Monday, July 10 the stock rating was maintained by BMO Capital Markets with “Hold”. The firm has “Buy” rating by Cowen & Co given on Friday, September 22. Barclays Capital maintained Abbott Laboratories (NYSE:ABT) rating on Thursday, January 25. Barclays Capital has “Overweight” rating and $70 target. Stifel Nicolaus maintained Abbott Laboratories (NYSE:ABT) rating on Friday, September 22. Stifel Nicolaus has “Buy” rating and $58.0 target. The firm has “Hold” rating by Citigroup given on Thursday, August 17. The company was maintained on Monday, June 26 by RBC Capital Markets. The firm has “Buy” rating by RBC Capital Markets given on Wednesday, January 24.

More notable recent Abbott Laboratories (NYSE:ABT) news were published by: Streetinsider.com which released: “Abbott (ABT) Reports 5-Yr FAME 2 Study Showing Positive Outcomes of Patients Using Diagnostic Tool” on May 22, 2018, also Streetinsider.com with their article: “Stifel Sees Minimal Impact from Abbott Labs (ABT) HeartMate III ‘Dear Doc Letter'” published on May 23, 2018, Streetinsider.com published: “Abbott (ABT) Reports Positive Outcomes for First 100 Patients in Global Study of Investigational Tendyne Transcatheter …” on May 23, 2018. More interesting news about Abbott Laboratories (NYSE:ABT) were released by: Seekingalpha.com and their article: “Abbott’s stent guide improved outcomes in long-term study” published on May 22, 2018 as well as Streetinsider.com‘s news article titled: “JPMorgan Remains Positive on Abbott (ABT), Expects Limited Impact from LVAD Recall” with publication date: May 22, 2018.

Analysts await Abbott Laboratories (NYSE:ABT) to report earnings on July, 19. They expect $0.71 earnings per share, up 14.52% or $0.09 from last year’s $0.62 per share. ABT’s profit will be $1.24B for 21.76 P/E if the $0.71 EPS becomes a reality. After $0.59 actual earnings per share reported by Abbott Laboratories for the previous quarter, Wall Street now forecasts 20.34% EPS growth.

Reilly Financial Advisors Llc, which manages about $679.11 million and $704.29 million US Long portfolio, upped its stake in Spdr Series Trust (ITR) by 10,210 shares to 10,238 shares, valued at $350,000 in 2017Q4, according to the filing. It also increased its holding in Kimberly Clark Corp (NYSE:KMB) by 75,074 shares in the quarter, for a total of 77,465 shares, and has risen its stake in Pioneer Nat Res Co (NYSE:PXD).

Investors sentiment increased to 0.91 in Q4 2017. Its up 0.04, from 0.87 in 2017Q3. It is positive, as 52 investors sold ABT shares while 558 reduced holdings. 123 funds opened positions while 430 raised stakes. 1.22 billion shares or 0.64% more from 1.21 billion shares in 2017Q3 were reported. Fragasso Group Inc Inc stated it has 0.06% in Abbott Laboratories (NYSE:ABT). Nuveen Asset Mgmt Ltd Co, a Illinois-based fund reported 117,515 shares. Edmp Inc holds 0.91% in Abbott Laboratories (NYSE:ABT) or 18,217 shares. Shell Asset Mgmt reported 374,871 shares stake. Eagle Ridge Management has 184,872 shares for 1.63% of their portfolio. Sit Inv Associates reported 618,970 shares. Meyer Handelman Company reported 100,785 shares stake. Palladium Limited Liability Co owns 0.23% invested in Abbott Laboratories (NYSE:ABT) for 55,114 shares. Canal reported 40,000 shares. North Star Asset Mgmt Incorporated holds 1.42% or 276,415 shares. Nuwave Management Ltd Liability Company has 710 shares for 0.05% of their portfolio. Harding Loevner LP holds 0.75% of its portfolio in Abbott Laboratories (NYSE:ABT) for 2.33M shares. Thompson Davis & Incorporated reported 0.13% stake. 683,266 are held by Brown Advisory Incorporated. State Board Of Administration Of Florida Retirement System accumulated 2.44M shares or 0.37% of the stock.

Since December 14, 2017, it had 1 buy, and 21 insider sales for $23.88 million activity. 459 shares were sold by PEDERSON MICHAEL J, worth $27,213. Funck Robert E sold $71,970 worth of Abbott Laboratories (NYSE:ABT) on Wednesday, February 28. $58,635 worth of stock was sold by Watkin Jared on Wednesday, February 28. $53,369 worth of Abbott Laboratories (NYSE:ABT) shares were sold by Salvadori Daniel Gesua Sive. 42,665 shares were sold by Ford Robert B, worth $2.69M. $1.73 million worth of stock was sold by Blaser Brian J on Wednesday, January 31.

Credit Agricole S A, which manages about $1.49B US Long portfolio, decreased its stake in Broadridge Finl Solutions Inc (NYSE:BR) by 32,535 shares to 31,573 shares, valued at $2.86 million in 2017Q4, according to the filing. It also reduced its holding in Intel Corp (NASDAQ:INTC) by 5.65M shares in the quarter, leaving it with 210,638 shares, and cut its stake in Michael Kors Hldgs Ltd (NYSE:KORS).

Abbott Laboratories (NYSE:ABT) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>